Business
MedMira Gains Market Traction in Eastern Europe and Latin America - Multiplo Triple Test to be Introduced as Market Expansion Continues
HALIFAX, April 15 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a global m...
About this update from Medmira Inc.
[{"type":"text","content":"\n\n\n\nHALIFAX, April 15 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,\nNASDAQ: MMIRF), a global market leader in premium rapid diagnostic solutions,\nannounced today that it is gaining healthy market traction and realizing\nsteady sales of the company's rapid HIV tests in Eastern Europe and Colombia.\nTo date two orders have been shipped to Romania and four orders to Colombia.\nMedMira's rapid HIV tests have received a very favourable response from the\ncompany's distributors and their customers in these markets\n\n\n"Both our Romania and Colombia distributors are achieving positive sales\nresults with our rapid HIV test and identifying emerging market opportunities\nfor additional MedMira products. Demand for quality rapid diagnostics in these\nmarkets will continue to grow and our reputation as a world class developer\nand manufacturer will ensure MedMira a lead position within the marketplace,"\nsaid Hermes Chan, President & CEO of MedMira Inc.\n\n\nMedMira's Eastern European distributor, S.C. Roned International S.R.L.,\nplans to expand its diagnostics to other territories with the Multiplo(TM)\nRapid HBV/HIV/HCV Antibody Test (Multiplo HBV/HIV/HCV). Multiplo HBV/HIV/HCV\nis one of MedMira's newest generation rapid diagnostic tests, and can\nsimultaneously detect antibodies to HIV and the hepatitis B and C viruses in a\nsingle drop of blood.\n\n\nChan continued, "We will be working closely with our distribution\npartners in Eastern Europe, Latin America, and other international markets to\nexplore opportunities to introduce the Multiplo HBV/HIV/HCV test and expand\nMedMira's potential revenue streams."\n\n\nThe prevalence of HCV infection in HIV-infected patients has been found\nto be particularly high in Europe, where an average of 40% of HIV-infected are\nco-infected with HCV. HBV is 100 times more infectious than HIV, and more than\n70% of HIV-infected people have been found to have a blood marker indicating\npast or present HBV infection (WHO, 2006). A higher risk of death is\nassociated with individuals infected with HIV along with both HCV and HBV,\nmaking identification of these co-infections very critical in determining the\nbest course of treatment (www.hivinsite.ucsf.edu).\n\n\nAbout MedMira\n\n\nMedMira is a leading developer and manufacturer of flow-through rapid\ndiagno...